B. Riley keeps Buy rating on Altimmune after Q4 results, pipeline updates
The Fly

B. Riley keeps Buy rating on Altimmune after Q4 results, pipeline updates

B. Riley noted that Altimmune provided several pipeline updates along with reporting Q4 results, notably pertaining to pemvidutide execution through mid-stage clinical development. The Phase 2 MOMENTUM non-diabetes obesity study remains on track to report 160-subject 24-week interim analysis in the second half of March and final 48-week readout in Q4 and a new Phase 2 biopsy-proven NASH study is guided for mid-2023 initiation, said the analyst, noting in regards to the latter that the firm is "encouraged by the pace of execution to capitalize on the best-in-indication liver fat reduction" noted in the company’s recently concluded Phase Ib NAFLD study. B. Riley reiterates a Buy rating and $26 price target on Altimmune shares.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on ALT:

Related Articles
GlobeNewswireCORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
TheFlyAltimmune presents results of Phase 2 MRI-based body composition sub-study
GlobeNewswireAltimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App